HYDERABAD, INDIA (10 Nov’ 2015) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 10th Nov’ 2015 at Hyderabad.
Financial Highlights for the 2nd Quarter ended September’ 2015 (QoQ):
Growth in revenue INR 1226 Mn vs Rs 1061 Mn - up by 15.55%
Growth in PAT INR 247 Mn vs. Rs 202 Mn - up by 22.23%
Growth in EBIDTA INR 365 Mn vs. Rs 301Mn - up by 21.27%
Financial Highlights for the Half year ended September’ 2015:
Growth in revenue INR 2286 Mn vs Rs 2839 Mn - down by 19.47%
Growth in PAT INR 450 Mn vs. Rs 596 Mn - down by 24.53%
Growth in EBIDTA INR 666 Mn vs. Rs 938 Mn - down by 28.94%
Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of INR 310 Mn (13.56% on revenue) for the half year ended Sept’ 2015.
Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations during this quarter.
Based on the authorization during last Board meeting, Suven has incorporated a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA and the same become operational from October 2015.
For more information on Suven please visit our Web site at http://www.suven.com
Help employers find you! Check out all the jobs and post your resume.
